Metabolomics and Microbiomics in Cardiovascular Diseases
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Heart Failure
- Cardiomyopathies
- Dilated Cardiomyopathy
- Ischemic Cardiomyopathy
- Myocardial Infarction, Acute
- NSTEMI - Non-ST Segment Elevation MI
- Sepsis
- STEMI - ST Elevation Myocardial Infarction
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular patients is still lacking. The acute, critical or progressive disease status predestinies to relevant changes in cardiovascular metobolism. High-risk patients in the present trial comprise those with acute ...
Scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular patients is still lacking. The acute, critical or progressive disease status predestinies to relevant changes in cardiovascular metobolism. High-risk patients in the present trial comprise those with acute heart failure, myocardial infarction (STEMI and NSTEMI), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy with severely reduced left ventricular ejection fraction (LVEF <35%). Therfore this study investigates to identify disease-specific patterns of metabolic and microbiomic changes. These patterns may help to understand pathophysiology at the metabolic stages and find out those patients being at highest risk of adverse future outcome.
Tracking Information
- NCT #
- NCT04146701
- Collaborators
- Not Provided
- Investigators
- Study Director: Michael Behnes, PD Dr. University Medical Center Mannheim
Get Well Soon